Workflow
Boumarang, Inc. Files S-1 Registration Statement with the U.S. Securities and Exchange Commission
Globenewswire· 2025-12-18 05:20
IRVINE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Boumarang, Inc. ("Boumarang"), a leader in hydrogen-powered autonomous aerial drone systems, today announced that it has filed a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC). This filing represents a significant milestone in Boumarang's strategic growth trajectory and demonstrates the Company's commitment to transparency and regulatory compliance as it seeks to access public capital markets. The Form S-1 Registrat ...
Fermi Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation
Globenewswire· 2025-12-18 05:19
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Fermi Inc. (Nasdaq: FRMI) for potential securities law violations. Investors who have lost money in their Fermi Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/frmi. What is this all about? Shares of Fermi fell over 30% on December 12, dropping below their IPO price of $21 per share, after the company disclosed that a prospective c ...
NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS
TMX Newsfile· 2025-12-18 05:18
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that it has filed a registration statement on Form F-10 (the "Registration Statement") with the United States Securities and Exchange Commission ("SEC") in accordance with the ...
United Airlines' Growing Maturity Demands Investor Attention
Seeking Alpha· 2025-12-18 05:18
Airline industry stocks have not had a great 2025. Tariff threats and general economic uncertainty in the first few months of the year morphed into a strong second quarter – for airlines that had premium revenue andAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than ...
Delta president Glen Hauenstein, who helped turn airline into industry profit leader, to retire in February
CNBC· 2025-12-18 05:17
Glen Hauenstein, president of Delta Air Lines Inc., left, and Ed Bastian, chief executive officer of Delta Air Lines Inc., right, ring the opening bell on the floor of the New York Stock Exchange (NYSE) in New York, US, on Wednesday, Nov. 12, 2025.Delta Air Lines President Glen Hauenstein, who propelled the carrier to become the industry's profit leader and championed the airline's lucrative embrace of travelers willing to spend a little extra for a more luxurious travel experience, is retiring in February. ...
Starfighters Space Announces Closing of its Reg A Initial Public Offering
Businesswire· 2025-12-18 05:17
CAPE CANAVERAL, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. ("Starfighters†or "the Company†), the innovative aerospace company, owner and operator of the world's largest commercial supersonic aircraft fleet, out of NASA's Kennedy Space Center, today announced the completion of its Initial Public Offering ("IPO†), raising $40 million through the sale of 11,142,061 shares of common stock (the "Common Stock†) at a public offering price of $3.59 per share. This final closing resulted in the issuance o ...
Adobe: In The AI Era, Stable Is No Longer Sexy
Seeking Alpha· 2025-12-18 05:16
The last time I wrote about Adobe Inc (NASDAQ: ( ADBE )), in June 2025, I analyzed the company’s second quarter results and examined the key takeaways, with a particular emphasis on how the company’sAn independent investor in the Indian and US equity markets with a CFA Charter and a PhD in Finance from University of Durham, U.K. I hold an Honorary Associate Professor in Finance and Corporate Governance title at Brunel University London. I have a YouTube and a Podcast channel, titled The Stock Doctor,' where ...
Class Action Filed Against DeFi Technologies (DEFT) Seeking Recovery for Investors – Contact The Gross Law Firm
Globenewswire· 2025-12-18 05:16
NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DeFi Technologies (NASDAQ: DEFT). Shareholders who purchased shares of DEFT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/defi-technologies-loss-submission-form/?id=180552&from=3 CLASS PERIOD: May 12, 2 ...
AI stocks: Energy and transportation plays, valuation concerns, and is it time to sell Mag 7?
Youtube· 2025-12-18 05:15
You know, obviously there's there's been a volatile element that has come into the AI sentiment here. >> Absolutely. >> A lot of it is centered around Oracle and sort of funding of these projects, private credit and its involvement in all of this.Like what are your thoughts on this. Yeah, I mean we've definitely seen um you know some concern building you know kind of within the markets you know just in terms of the amount of capex that is being committed you know kind of Oracle and the open AI kind of side ...
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
Prnewswire· 2025-12-18 05:15
DUBLIN, Dec. 17, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor events: Zanidatamab HERIZON-GEA-01 Investor Webcast on Friday, January 9, 2026 About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing potentially life-changing medicines for people with serious disease ...